Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

@article{Furberg1995NifedipineDI,
  title={Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.},
  author={C. Furberg and B. Psaty and J. Meyer},
  journal={Circulation},
  year={1995},
  volume={92 5},
  pages={
          1326-31
        }
}
BACKGROUND The purpose of this study was to assess the effect of the dose of nifedipine, a dihydropyridine calcium antagonist, on the increased risk of mortality seen in the randomized secondary-prevention trials and to review the mechanisms by which this adverse effect might occur. METHODS AND RESULTS We restricted the dose-response meta-analysis to the 16 randomized secondary-prevention trials of nifedipine for which mortality data were available. Recent trials of any calcium antagonist and… Expand
Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients.
TLDR
The current analysis does not support the claim that calcium antagonist therapy in patients with chronic coronary artery disease, whether myocardial infarction survivors or others harbors an increased risk of mortality. Expand
REVIEW OF THE AVAILABLE EVIDENCE ABOUT NIFEDIPINE IN THE TREATMENT OF HYPERTENSION
  • 2004
Findings from a meta-analysis published in 1995 suggested that in the secondary prevention of myocardial infarction, short-acting nifedipine in moderate to high doses causes an increase in totalExpand
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension
TLDR
Clinical studies evaluating the use of nifedipine when compared to placebo as well as other anti-hypertensive therapies are described in an attempt to identify the most appropriate place in therapy for this class of medications and to further clarify its utilization in high-risk patients. Expand
Nifedipine and Cancer Mortality: Ten-Year Follow-up of 2607 Patients After Acute Myocardial Infarction
TLDR
The current analysis shows no evidence of an increased risk of cancer mortality in a large number of patients treated at baseline with nifedipine. Expand
Sudden Cardiac Death in Patients with Hypertension
TLDR
Although it was suggested in the 2 recent case-control studies that recipients of β-blockers are also at an increased risk of sudden death, further studies are required to confirm this finding, particularly since these drugs have several well-documented cardioprotective effects. Expand
Morbidity and mortality with dihydropyridines.
TLDR
It can be concluded that the available evidence on the use of dihydropyridine CaAs shows that these agents have a beneficial effect on morbidity, and whether this effect is greater than that obtained with conventional therapies, such as diuretics and/or beta-blockers, will be shown by the STOP-2 Study, which is expected to be completed in 1998. Expand
Calcium antagonism in perspective: new data on diltiazem in unstable angina.
TLDR
It was concluded that intravenous diltiazem, compared with intravenous nitroglycerin, significantly reduces ischaemic events and can be used safely in patients with unstable angina and that first-generation dihydropyridines should not be used in acute ischaemia syndromes. Expand
Use of nifedipine in the treatment of hypertension
TLDR
It was demonstrated that nifedipine confers cardiovascular protection as effectively as diuretics in high-risk patients, with a smaller incidence of adverse metabolic consequences, supporting the use of calcium channel blockers in hypertensive patients – especially those at high cardiovascular risk. Expand
Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
TLDR
The results of these 4 placebo-controlled trials confirm that when taken at the recommended doses of 50 and 100 mg once daily, mibefradil is an effective, safe, and well-tolerated therapy for the treatment of mild-to-moderate essential hypertension. Expand
Safety of Immediate-Release Nifedipine
TLDR
Although nifedipine IR may cause major adverse events, the incidence seems lower than previously believed and may be an option to treat elevated blood pressure in hospitalized patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials.
TLDR
The routine use of class I antiarrhythmic agents after myocardial infarction is associated with increased mortality and the limited data on amiodarone appear promising. Expand
Nifedipine in unstable angina: a double-blind, randomized trial.
TLDR
The addition of nifedipine to conventional therapy is safe and effective in unstable angina and was particularly marked in patients with ST-segment elevation during angina. Expand
Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study.
TLDR
Early routine administration of nifedipine in acute MI, other than to patients in whom it may be specifically indicated (eg, those with Prinzmetal's variant angina or severe hypertension) may be hazardous and seems to be contraindicated. Expand
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.
TLDR
Calcium channel blockers do not reduce the risk of initial or recurrent infarct or death when given routinely to patients with acute myocardial infarction or unstable angina. Expand
Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison.
Preliminary clinical and laboratory observations suggest that nifedipine might prevent progression of threatened myocardial infarction by reversing coronary spasm or might limit necrosis during theExpand
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
TLDR
It is concluded that neither encainide nor flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia. Expand
Effect of early treatment with nifedipine in suspected acute myocardial infarction.
TLDR
Early treatment with nifedipine did not reduce enzymatically determined infarct size or one month mortality in patients with AMI, or reduce one month morbidity or mortality in Patients with ACI. Expand
Nifedipine and conventional therapy for unstable angina pectoris: a randomized, double-blind comparison.
TLDR
For the study population as a whole therapy with nifedipine alone was equivalent to conventional therapy for unstable angina, although this overall equivalence may result from a combination of superiority of nifingipine therapy in patients previously receiving beta-blocker therapy and superiority of beta- blockers in patients not previously receiving Beta-blockers. Expand
Trial of early nifedipine in acute myocardial infarction: the Trent study.
TLDR
Subgroup analysis also did not suggest any particular group of patients with suspected acute myocardial infarction who might benefit from early nifedipine treatment in the dose studied. Expand
Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial.
TLDR
There were more cardiovascular side effects with nicardipine than with placebo, with at least 3 patients having increased angina judged by investigators as probably related to the drug. Expand
...
1
2
3
4
5
...